[Comparison of treatment outcome in patients with rheumatoid arthritis treated with TFX- Polfa or gold salts after a one year follow up].
Thirty five patients with rheumatoid arthritis were given TFX Polfa, initially everyday in the intramuscular injections in the dose of 10 mg TFX protein for 60 days, followed by 1 injection of 10 mg TFX protein a week for 10 months. Other 30 patients with rheumatoid arthritis treated with gold salts were used for comparison. Several clinical and laboratory tests were performed before the treatment and after 1 year. A one-year therapy significantly improved all clinical parameters in both groups. A significant increase in hemoglobin and erythrocyte count was noted in patients treated with TFX. A significant decrease in the markers of inflammation was seen. A percentage of both early and delayed E rosettes increased highly significantly. The obtained results suggest that TFX Polfa is efficient in these cases of the rheumatoid arthritis which cannot be treated with gold salts.
Lewandowicz
J
J
Zespołu Reumatologicznego Instytutu Medycyny Wewnetrznej AM, Lodzi.
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006046:Gold / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D013949:Thymus Extracts / Q000627:therapeutic use*
C019108:TFX; D013949:Thymus Extracts; D006046:Gold
Porównanie wyników leczenia chorych na reumatoidalne zapalenie stawów preparatem TFX-Polfa albo solami złota po rocznej obserwacji.